Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Change in Account Payables (2016 - 2025)

Cytokinetics (CYTK) has disclosed Change in Account Payables for 16 consecutive years, with $13.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables changed N/A to $13.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.4 million, a N/A change, with the full-year FY2025 number at $2.7 million, up 159.4% from a year prior.
  • Change in Account Payables was $13.1 million for Q4 2025 at Cytokinetics, up from -$4.6 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $13.1 million in Q4 2025 to a low of -$10.3 million in Q1 2024.
  • A 5-year average of $10764.7 and a median of -$422000.0 in 2021 define the central range for Change in Account Payables.
  • Biggest YoY gain for Change in Account Payables was 907.11% in 2022; the steepest drop was 630.89% in 2022.
  • Cytokinetics' Change in Account Payables stood at $3.9 million in 2021, then skyrocketed by 238.29% to $13.0 million in 2022, then plummeted by 40.9% to $7.7 million in 2023, then plummeted by 77.73% to $1.7 million in 2024, then skyrocketed by 660.1% to $13.1 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Change in Account Payables are $13.1 million (Q4 2025), -$4.6 million (Q1 2025), and $1.7 million (Q3 2024).